Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation (RESTORE-1)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Sponsor: InCarda Therapeutics, Inc.
Terminated
Limited efficacy upon blinded review
Other Paroxysmal Atrial Fibrillation trials with similar outcome
A PHASE3 clinical study on Paroxysmal Atrial Fibrillation, this trial is terminated or withdrawn. The trial is conducted by InCarda Therapeutics, Inc. and has accumulated 8 data snapshots since 2022. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Jul 2023 — Nov 2023 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Jan 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2022 — Jan 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — May 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- InCarda Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Barcelona, Spain , Bridgeport, United States , Budapest, Hungary , Cincinnati, United States , Cleveland, United States , Davis, United States , Deventer, Netherlands , Ede, Netherlands , Goes, Netherlands and 24 more locations